Webinars
Upcoming Global Webinar
“Cost reduction of viral vector processes by using upstream bioprocessing with 3D nanofiber-based cell culture systems”
Tuesday April 1st 2025
Time: 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
To enhance the large-scale production of gene therapies, adopting advanced upstream technologies that boost viral vector yields and productivity is crucial. Innovative platforms, such as nanofiber-based cell culture systems, offer an efficient strategy, increasing viral vector titers up to 3x compared to traditional methods.
On April 1st, Christel Fenge (Chief Technology Officer, Cellevate), Geddy Hamblen (Application Manager North America, Cellevate) and Rob Noel (Commercialisation Consultant, 55Biomarkets), will discuss how nanofiber-based cell culture systems provide cost savings in material, labor, and waste, and reduce seed train time in viral vector manufacturing.
Attend this webinar to:
- Discover sustainable cellulose nanofiber microcarriers that interact with cells to form 3D cell-dense spheroids, providing up to 60x higher surface area compared to bead-based microcarriers.
- Find out why using nanofiber microcarriers provides up to 70% cost reduction in the production of one dose of a gene therapy.
- See data showing that novel nanofibers offer up to 3x higher yields than traditional microcarriers and >90% transfection efficiency.
In collaboration with Cell & Gene Therapy Insights.
Past Webinars
Global Launch Webinar Cellevat3d® nanofiber-based cell culture systems
“Revolutionizing upstream gene therapy manufacturing with nanofiber microcarriers”
November 27, 2024
Are you looking for new cell culture systems to improve your AAV upstream bioprocessing? Improved cell culture product yield, faster processes, and scale-up can all result in an enhanced process economy in upstream gene therapy manufacturing.
Join us for an exclusive launch webinar of the world’s first nanofiber-based microcarriers designed to boost viral vector titers and improve productivity to much higher levels than current processes in gene therapy manufacturing. We will present data from scaling up AAV processes from cell culture flasks to stirred tank bioreactors.
Don’t miss the chance to listen to Associate Professor in Medical Innovation, John Counsell, PhD, UCL, presenting exciting benchmarking results from the use of Cellevat3d® nanofiber-based microcarriers in AAV9 production compared to current standard microcarriers.
Speakers:
John Counsell, PhD
Associate Professor in Medical Innovation at UCL Research Department of Targeted Intervention
Laura Chirica, PhD
CEO at Cellevate AB
Linda Mellby, PhD
Vice President, R&D at Cellevate AB
In collaboration with Cell & Gene Therapy Insights.
